Arch Therapeutics Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Arch Therapeutics Inc 's ROA in the third quarter of 2024?
Arch Therapeutics Inc recorded a cumulative net loss of $-12 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -730.16%.

However, within the Healthcare sector 1034 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2024 quarter, so far to 5107, from total ROA ranking in the second quarter of 2024 at 5138.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2024) III. Quarter	(Mar 31 2024) II. Quarter	(Dec 31 2023) I. Quarter	(Sep 30 2023) IV. Quarter	(Jun 30 2023) III. Quarter
Y / Y Total Assets Change	-10.65 %	-3.31 %	-25.7 %	-24.79 %	-0.56 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-12	-8	-8	-7	-6
Return On Assets (TTM)	-730.16 %	-489.86 %	-453.47 %	-369.1 %	-312.39 %
ARTH's Total Ranking	# 5107	# 5138	# 5899	# 5286	# 5381
Total Assets (TTM) in million	1	2	2	2	2
Seq. Total Assets Change	-9.24 %	-15.47 %	-6.96 %	25.18 %	-1.79 %
Seq. Net Income Change	-	-	-	-	-

ARTH's 5 Years Annual ROA >> Back to ARTH Management Effectiveness >> Compare ARTH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 234
Sector	# 1035
Overall	# 5008

Return On Assets Statistics
High	Average	Low
57.07 %	-187.69 %	-730.15 %
(Mar 31 2015)		(Jun 30 2024)

Financial Statements
Arch Therapeutics Inc 's Assets	$ 1 million	ARTH's Balance sheet
Arch Therapeutics Inc 's Income	$ -6 million	Quarterly ARTH's Income Statement
ARTH's Income by Division		See ARTH's Income by Division

Annual Return On Assets	(Sep 30 2023) FY 2023	(Sep 30 2022) FY 2022	(Sep 30 2021) FY 2021	(Sep 30 2020) FY 2020	(Sep 30 2019) FY 2019
Y / Y Total Assets Change	-24.79 %	-29.18 %	70.92 %	-25.88 %	-40.04 %
Total Assets in million	2	3	4	2	3
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-7	-5	-6	-5	-5
Annual Return On Assets	-356.6 %	-202.63 %	-169.74 %	-218.1 %	-156.7 %

ARTH's 5 Years Annual ROA >> Back to ARTH Management Effectiveness >> Compare ARTH ROA to its Competitors

More Return On Assets Ratios
ARTH's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ARTH's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ARTH's Competitors
Subscribers only: Roa for Arch Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for ARTH's Customers

You may also want to know
ARTH's Roi	ARTH's Inventory Turnover Ratio	ARTH's Growth Rates	ARTH's Dividend Comparisons
	ARTH's Profitability Ratios	ARTH's Asset Turnover Ratio	ARTH's Dividend Growth
ARTH's Roe	ARTH's Valuation Ratios	ARTH's Financial Strength Ratios	ARTH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:11:07+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.